ScoreWhy is HLS Therapeutics, Inc. ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.40 times
- Poor long term growth as Net Sales has grown by an annual rate of 1.71% and Operating profit at 8.20% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.40 times
- The company has reported losses. Due to this company has reported negative ROE
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 54.86%, its profits have risen by 37.9%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is HLS Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
HLS Therapeutics, Inc.
10.3%
1.52
34.69%
S&P/TSX 60
30.34%
1.54
14.62%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.63%
EBIT Growth (5y)
10.46%
EBIT to Interest (avg)
-1.32
Debt to EBITDA (avg)
3.40
Net Debt to Equity (avg)
0.68
Sales to Capital Employed (avg)
0.40
Tax Ratio
28.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.57%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.63
EV to EBIT
-32.70
EV to EBITDA
7.65
EV to Capital Employed
1.39
EV to Sales
2.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.25%
ROE (Latest)
-18.33%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at CAD -8.41 MM
ROCE(HY)
Highest at -20.49%
INVENTORY TURNOVER RATIO(HY)
Highest at 4.4 times
-5What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 10.45% (YoY
CASH AND EQV(HY)
Lowest at CAD 31.58 MM
INTEREST(Q)
Highest at CAD 3.37 MM
Here's what is working for HLS Therapeutics, Inc.
Net Profit
Higher at CAD -8.41 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CAD MM)
Net Profit
At CAD -8.41 MM has Grown at 52.39%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CAD MM)
Inventory Turnover Ratio
Highest at 4.4 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for HLS Therapeutics, Inc.
Interest
At CAD 3.37 MM has Grown at 40.31%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CAD MM)
Interest
Highest at CAD 3.37 MM
in the last five periods and Increased by 40.31% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CAD MM)
Cash and Eqv
Lowest at CAD 31.58 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 10.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
